





**ALEMBIC LIMITED**  
CIN:L26100GJ1907PLC000033  
Regd. Office: Alembic Road, Vadodara 390 003  
Ph:0265 6637000  
www.alembiclimited.com Email:alembic.investors@alembic.co.in

**Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2026**

| Sr. No | Particulars                                                                         | Quarter Ended             |                         |                           | Rs. in Lakhs            |
|--------|-------------------------------------------------------------------------------------|---------------------------|-------------------------|---------------------------|-------------------------|
|        |                                                                                     | 30.06.2026<br>(Unaudited) | 31.03.2026<br>(Audited) | 30.06.2025<br>(Unaudited) | 31.03.2026<br>(Audited) |
| 1      | Revenue from Operations                                                             | 4,874                     | 6,004                   | 4,975                     | 23,999                  |
| 2      | Other Income                                                                        | 596                       | 214                     | 359                       | 7,297                   |
| 3      | <b>Total Income</b>                                                                 | <b>5,471</b>              | <b>6,218</b>            | <b>5,334</b>              | <b>31,296</b>           |
| 4      | <b>Expenses</b>                                                                     |                           |                         |                           |                         |
|        | Cost of Materials Consumed                                                          | 493                       | 404                     | 345                       | 1,388                   |
|        | Cost of Construction                                                                | 862                       | 1,463                   | 1,010                     | 6,002                   |
|        | Changes in Inventories of Finished Goods and WIP                                    | (51)                      | (65)                    | 174                       | 255                     |
|        | Employee Benefit Expenses                                                           | 1,046                     | 1,174                   | 783                       | 3,744                   |
|        | Finance Costs                                                                       | 60                        | 57                      | 59                        | 228                     |
|        | Depreciation and amortisation expense                                               | 348                       | 334                     | 279                       | 1,239                   |
|        | Other Expenses                                                                      | 979                       | 1,006                   | 705                       | 3,564                   |
|        | <b>Total Expenses</b>                                                               | <b>3,737</b>              | <b>4,374</b>            | <b>3,356</b>              | <b>16,420</b>           |
| 5      | <b>Profit Before Tax (3-4)</b>                                                      | <b>1,734</b>              | <b>1,844</b>            | <b>1,978</b>              | <b>14,876</b>           |
| 6      | <b>Tax Expenses</b>                                                                 |                           |                         |                           |                         |
|        | Current Tax                                                                         | 193                       | 566                     | 202                       | 2,263                   |
|        | Deferred Tax                                                                        | (29)                      | 287                     | (3)                       | (10)                    |
|        | Short / (Excess) Provision of earlier years                                         | -                         | 30                      | -                         | 30                      |
| 7      | <b>Net Profit after tax for the Period</b>                                          | <b>1,570</b>              | <b>961</b>              | <b>1,780</b>              | <b>12,593</b>           |
| 8      | <b>Share of Associate's Profit/(Loss)</b>                                           | <b>4,919</b>              | <b>5,752</b>            | <b>4,384</b>              | <b>19,145</b>           |
| 9      | <b>Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)</b>           | <b>6,489</b>              | <b>6,713</b>            | <b>6,164</b>              | <b>31,738</b>           |
| 10     | <b>Other Comprehensive Income</b>                                                   |                           |                         |                           |                         |
|        | A (i) Items that will not be reclassified to Profit or (Loss)                       | 7,048                     | (11,724)                | 482                       | (10,562)                |
|        | (ii) Income tax relating to items that will not be reclassified to Profit or (Loss) | (752)                     | 1,241                   | (69)                      | 925                     |
|        | B (i) Items that will be reclassified to Profit or (Loss)                           | 90                        | 384                     | 31                        | 882                     |
|        | (ii) Income tax relating to items that will be reclassified to Profit or Loss       | (14)                      | -                       | -                         | -                       |
| 11     | <b>Total Comprehensive Income/(Loss) for the Period</b>                             | <b>12,860</b>             | <b>(3,387)</b>          | <b>6,609</b>              | <b>22,983</b>           |
| 12     | Paid up Equity Share Capital (Face Value of Rs 2/- per share)                       | 5,135.64                  | 5,135.64                | 5,135.64                  | 5,135.64                |
| 13     | Other Equity (excluding Revaluation Reserve)                                        |                           |                         |                           | 2,24,927                |
| 14     | Earnings per equity share (FV Rs. 2/- per share)<br>Basic & Diluted (In Rs.)        | 2.53                      | 2.61                    | 2.40                      | 12.36                   |



**Alembic Limited**

**Segment wise Consolidated Revenue and Results**

| Sr. No | Particulars                                                                               | Quarter Ended             |                         |                           | Rs. In Lakhs            |
|--------|-------------------------------------------------------------------------------------------|---------------------------|-------------------------|---------------------------|-------------------------|
|        |                                                                                           | 30.06.2026<br>(Unaudited) | 31.03.2026<br>(Audited) | 30.06.2025<br>(Unaudited) | 31.03.2026<br>(Audited) |
| 1      | <b>Segment Revenue</b>                                                                    |                           |                         |                           |                         |
|        | Revenue from Operations                                                                   |                           |                         |                           |                         |
|        | a. Active Pharmaceutical Ingredients Business                                             | 1,171                     | 983                     | 1,295                     | 4,659                   |
|        | b. Real Estate Business                                                                   | 3,703                     | 5,021                   | 3,680                     | 19,340                  |
|        | <b>Total Income from Operations (Net)</b>                                                 | <b>4,874</b>              | <b>6,004</b>            | <b>4,975</b>              | <b>23,999</b>           |
| 2      | <b>Segment Results (Profit (+)/ Loss (-) before Taxes and Interest from each segment)</b> |                           |                         |                           |                         |
|        | a. Active Pharmaceutical Ingredients Business                                             | 166                       | (117)                   | 273                       | 565                     |
|        | b. Real Estate Business                                                                   | 1,398                     | 2,097                   | 1,594                     | 8,117                   |
|        | <b>Total</b>                                                                              | <b>1,564</b>              | <b>1,980</b>            | <b>1,867</b>              | <b>8,682</b>            |
|        | Unallocable Income and Expenditure                                                        |                           |                         |                           |                         |
|        | (i) Interest Expense                                                                      | (60)                      | (57)                    | (59)                      | (228)                   |
|        | (ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset              | 220                       | (121)                   | 171                       | 6,167                   |
|        | (iii) Other Income / (Expense)                                                            | 11                        | 42                      | 0                         | 255                     |
|        | <b>Total Profit Before Tax</b>                                                            | <b>1,734</b>              | <b>1,844</b>            | <b>1,978</b>              | <b>14,876</b>           |
| 3      | <b>Segment Assets</b>                                                                     |                           |                         |                           |                         |
|        | a. Active Pharmaceutical Ingredients Business                                             | 18,228                    | 18,081                  | 19,170                    | 18,081                  |
|        | b. Real Estate Business                                                                   | 52,873                    | 51,578                  | 46,822                    | 51,578                  |
|        | c. Unallocated                                                                            | 2,00,856                  | 1,89,291                | 1,86,165                  | 1,89,291                |
|        | <b>Total</b>                                                                              | <b>2,71,957</b>           | <b>2,58,951</b>         | <b>2,52,158</b>           | <b>2,58,951</b>         |
| 4      | <b>Segment Liabilities</b>                                                                |                           |                         |                           |                         |
|        | a. Active Pharmaceutical Ingredients Business                                             | 3,577                     | 3,480                   | 3,647                     | 3,480                   |
|        | b. Real Estate Business                                                                   | 7,765                     | 8,148                   | 10,857                    | 8,148                   |
|        | c. Unallocated                                                                            | 3,247                     | 2,814                   | 3,356                     | 2,814                   |
|        | <b>Total</b>                                                                              | <b>14,588</b>             | <b>14,442</b>           | <b>17,861</b>             | <b>14,442</b>           |

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025.

Place : Vadodara  
Date : 11th August, 2026



For Alembic Limited

Udit Amin  
Managing Director



**ALEMBIC LIMITED**  
CIN:L26100GJ1907PLC000033  
Regd. Office: Alembic Road, Vadodara 390 003  
Ph:0265 6637000  
www.alembiclimited.com Email:alembic.investors@alembic.co.in

**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2026**

| Sr. No. | Particulars                                                                         | Quarter Ended            |                        |                           | Rs. in Lakhs            |
|---------|-------------------------------------------------------------------------------------|--------------------------|------------------------|---------------------------|-------------------------|
|         |                                                                                     | 30.6.2026<br>(Unaudited) | 31.3.2026<br>(Audited) | 30.06.2025<br>(Unaudited) | 31.03.2026<br>(Audited) |
| 1       | Revenue from Operations                                                             | 4,627                    | 5,773                  | 4,789                     | 23,193                  |
| 2       | Other Income                                                                        | 555                      | 241                    | 346                       | 7,277                   |
| 3       | <b>Total Income</b>                                                                 | <b>5,182</b>             | <b>6,014</b>           | <b>5,134</b>              | <b>30,470</b>           |
| 4       | <b>Expenses</b>                                                                     |                          |                        |                           |                         |
|         | Cost of Materials Consumed                                                          | 493                      | 404                    | 345                       | 1,388                   |
|         | Cost of Construction                                                                | 862                      | 1,463                  | 1,010                     | 6,002                   |
|         | Changes in Inventories of Finished Goods and WIP                                    | (51)                     | (65)                   | 174                       | 255                     |
|         | Employee Benefit Expenses                                                           | 1,046                    | 1,174                  | 783                       | 3,744                   |
|         | Finance Costs                                                                       | 37                       | 37                     | 42                        | 157                     |
|         | Depreciation and amortisation expense                                               | 338                      | 325                    | 270                       | 1,201                   |
|         | Other Expenses                                                                      | 873                      | 841                    | 619                       | 3,035                   |
|         | <b>Total Expenses</b>                                                               | <b>3,598</b>             | <b>4,180</b>           | <b>3,243</b>              | <b>15,781</b>           |
| 5       | <b>Profit Before Tax (3-4)</b>                                                      | <b>1,584</b>             | <b>1,834</b>           | <b>1,892</b>              | <b>14,689</b>           |
| 6       | <b>Tax Expenses</b>                                                                 |                          |                        |                           |                         |
|         | Current Tax                                                                         | 159                      | 550                    | 180                       | 2,200                   |
|         | Deferred Tax                                                                        | (44)                     | 301                    | (0)                       | 5                       |
|         | Short / (Excess) Provision of earlier years                                         | -                        | 30                     | -                         | 30                      |
| 7       | <b>Net Profit after tax for the Period</b>                                          | <b>1,468</b>             | <b>953</b>             | <b>1,712</b>              | <b>12,454</b>           |
| 8       | <b>Other Comprehensive Income</b>                                                   |                          |                        |                           |                         |
|         | (i) Items that will not be reclassified to Profit or (Loss)                         | 7,062                    | (11,668)               | 495                       | (10,363)                |
|         | (ii) Income tax relating to items that will not be reclassified to Profit or (Loss) | (756)                    | 1,240                  | (71)                      | 898                     |
| 9       | <b>Total Comprehensive Income/(Loss) for the Period</b>                             | <b>7,774</b>             | <b>(9,476)</b>         | <b>2,136</b>              | <b>2,989</b>            |
| 10      | Paid up Equity Share Capital (Face Value of Rs 2/- per share)                       | 5,135.64                 | 5,135.64               | 5,135.64                  | 5,135.64                |
| 11      | Other Equity (excluding Revaluation Reserve)                                        |                          |                        |                           | 62,564                  |
| 12      | Earnings per equity share (FV Rs. 2/- per share)<br>Basic & Diluted (In Rs.)        | 0.57                     | 0.37                   | 0.67                      | 4.85                    |



## Alembic Limited

## Segment wise Standalone Revenue and Results

| Sr. No. | Particulars                                                                               | Quarter Ended             |                        |                           | Rs. in Lakhs            |
|---------|-------------------------------------------------------------------------------------------|---------------------------|------------------------|---------------------------|-------------------------|
|         |                                                                                           | 30.06.2026<br>(Unaudited) | 31.3.2026<br>(Audited) | 30.06.2025<br>(Unaudited) | 31.03.2026<br>(Audited) |
| 1       | <b>Segment Revenue</b>                                                                    |                           |                        |                           |                         |
|         | Revenue from Operations                                                                   |                           |                        |                           |                         |
|         | a. Active Pharmaceutical Ingredients Business                                             | 1,171                     | 983                    | 1,295                     | 4,659                   |
|         | b. Real Estate Business                                                                   | 3,455                     | 4,790                  | 3,493                     | 18,535                  |
|         | <b>Total Income from Operations (Net)</b>                                                 | <b>4,627</b>              | <b>5,773</b>           | <b>4,789</b>              | <b>23,193</b>           |
| 2       | <b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b> |                           |                        |                           |                         |
|         | a. Active Pharmaceutical Ingredients Business                                             | 166                       | (117)                  | 273                       | 565                     |
|         | b. Real Estate Business                                                                   | 1,224                     | 2,067                  | 1,490                     | 7,859                   |
|         | <b>Total</b>                                                                              | <b>1,391</b>              | <b>1,950</b>           | <b>1,763</b>              | <b>8,424</b>            |
|         | Unallocable Income and Expenditure                                                        |                           |                        |                           |                         |
|         | (i) Interest Expense                                                                      | (37)                      | (37)                   | (42)                      | (157)                   |
|         | (ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset              | 220                       | (121)                  | 171                       | 6,167                   |
|         | (iii) Other Income / (Expense)                                                            | 11                        | 42                     | 0                         | 255                     |
|         | <b>Total Profit Before Tax</b>                                                            | <b>1,584</b>              | <b>1,834</b>           | <b>1,892</b>              | <b>14,689</b>           |
| 3       | <b>Segment Assets</b>                                                                     |                           |                        |                           |                         |
|         | a. Active Pharmaceutical Ingredients Business                                             | 18,228                    | 18,081                 | 19,170                    | 18,081                  |
|         | b. Real Estate Business                                                                   | 51,262                    | 50,165                 | 45,574                    | 50,165                  |
|         | c. Unallocated                                                                            | 34,104                    | 27,524                 | 39,847                    | 27,524                  |
|         | <b>Total</b>                                                                              | <b>1,03,594</b>           | <b>95,770</b>          | <b>1,04,591</b>           | <b>95,770</b>           |
| 4       | <b>Segment Liabilities</b>                                                                |                           |                        |                           |                         |
|         | a. Active Pharmaceutical Ingredients Business                                             | 3,577                     | 3,480                  | 3,647                     | 3,480                   |
|         | b. Real Estate Business                                                                   | 6,707                     | 7,190                  | 9,944                     | 7,190                   |
|         | c. Unallocated                                                                            | 3,390                     | 2,954                  | 3,545                     | 2,954                   |
|         | <b>Total</b>                                                                              | <b>13,674</b>             | <b>13,625</b>          | <b>17,136</b>             | <b>13,625</b>           |

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2026 and year to date unaudited figures upto third quarter ended 31st December, 2025.

Place : Vadodara  
Date : 11th August, 2026



For Alembic Limited

Udit Amin  
Managing Director

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2026 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

#### 4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31<sup>st</sup> March, 2026. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26<sup>th</sup> May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.




The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: [www.cnkindia.com](http://www.cnkindia.com)

5. The statement includes results of the following entities:
- Alembic City Limited (Subsidiary)
  - Alembic Pharmaceuticals Limited (Associate)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs.1,241.62 lakhs, total net Profit/(Loss) after tax of Rs.(14.26) lakhs and total comprehensive income/(Loss) of Rs. (14.02) lakhs for the quarter ended 30<sup>th</sup> June, 2026. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs.4,919.02 lakhs and total comprehensive income of Rs. 4,984.09 lakhs for the quarter ended 30<sup>th</sup> June, 2026, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

  
Rachit Sheth


Partner

Membership No.158289

Place: Vadodara

Date: 11<sup>th</sup> August, 2026

UDIN: 26158289TTZWDT3534



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30<sup>th</sup> June, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: [www.cnkindia.com](http://www.cnkindia.com)

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | GURGOON | KOLKATA | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

#### 4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31<sup>st</sup> March, 2026. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26<sup>th</sup> May, 2023 and the appeal filed by the Company has been admitted.


Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date:11<sup>th</sup> August 2026

UDIN: 26158289BRLQIR2911

